Zenara Pharma, a totally owned subsidiary of Biophore India Pharmaceuticals, introduced that it has obtained approval from the Drugs Controller General of India (DCGI), to manufacture and sell Favipiravir tablets as a remedy choice for sufferers with gentle to reasonable signs of COVID-19. The pill, which can be bought below the model identify ‘Favizen’, is being manufactured at Zenar’s US FDA permitted facility right here, a press launch from the drug maker stated.
Jagadeesh Babu Rangisetty, Co-founder and Managing Director of the agency, stated, “In the ongoing pandemic, it has become extremely critical for pharmaceutical companies to quickly provide safe and effective treatment options for patients with COVID-19.
I am proud to say that we have our own in-house API and are not dependent on any imports for the production.
We believe that this will ensure stability and rapid production and availability of this treatment for the Indian market.”
The firm can be in talks with numerous establishments to make the tablets obtainable at discounted or no price to underprivileged sufferers, he added.
Zenara Pharma is in talks with a number of state establishments and several other hospitals in India to be certain that Favizen is available for sufferers in want.
The firm can be probably to tie up with different companions throughout the nation to improve affected person protection, it stated.
Internationally, Zenara has the manufacturing and distribution capabilities to enhance entry to this remedy around the globe and has already begun exports to the Middle East and Latin American nations.